OIG to beef up EHR, MU scrutiny

The Department of Health and Human Services Office of Inspector General (OIG) plans to significantly beef up its scrutiny of EHRs, according to its 2015 work plan.

EHRs is a new focus area in the plan which also continues most of OIG's EHR-related reviews from last year but, for the first time, will review hospitals' EHR contingency plans.

"We will determine the extent to which hospitals comply with contingency planning requirements of the Health Insurance Portability and Accountability Act [HIPAA]," according to the plan. "We will also compare hospitals' contingency plans with government- and industry-recommended practices. The HIPAA Security Rule requires covered entities to have a contingency plan that establishes policies and procedures for responding to an emergency or other occurrence that damages systems that contain protected health information." 

OIG already has been working on reviews that determine whether providers that received Meaningful Use (MU) incentive payments were entitled to the money; the success of Centers for Medicare & Medicaid Services (CMS) oversight of MU payments; CMS oversight of hospitals' security controls over networked medical devices integrated with EHR systems; and whether covered entities and business associates are adequately securing electronic patient protected helath information created or maintained by certified EHR technology.

Access the 2015 work plan.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.